These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 26729864)

  • 1. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
    Redmond WL; Gough MJ; Weinberg AD
    Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
    Jahan N; Talat H; Curry WT
    Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing the Generation of Eomes
    Emerson DA; Rolig AS; Redmond WL
    Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy.
    Linch SN; Redmond WL
    J Immunother Cancer; 2016; 4():31. PubMed ID: 27330804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.
    Murata S; Ladle BH; Kim PS; Lutz ER; Wolpoe ME; Ivie SE; Smith HM; Armstrong TD; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2006 Jan; 176(2):974-83. PubMed ID: 16393983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8
    Redmond WL; Linch SN
    Hum Vaccin Immunother; 2016 Oct; 12(10):2519-2522. PubMed ID: 27459422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic tumoricidal effect of combined hPD-L1 vaccine and HER2 gene vaccine.
    Zhang W; Wang S; Gu J; Gao Y; Wang Z; Zhang K; Mu N; Huang T; Li W; Hao Q; Xue X; Zhang W; Zhang Y; Zhang C
    Biochem Biophys Res Commun; 2018 Feb; 497(1):394-400. PubMed ID: 29438713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.
    Young KH; Baird JR; Savage T; Cottam B; Friedman D; Bambina S; Messenheimer DJ; Fox B; Newell P; Bahjat KS; Gough MJ; Crittenden MR
    PLoS One; 2016; 11(6):e0157164. PubMed ID: 27281029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.
    Mittal P; St Rose MC; Wang X; Ryan JM; Wasser JS; Vella AT; Adler AJ
    J Immunol; 2015 Dec; 195(12):5816-26. PubMed ID: 26561553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
    Moran AE; Polesso F; Weinberg AD
    J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.
    Metzger TC; Long H; Potluri S; Pertel T; Bailey-Bucktrout SL; Lin JC; Fu T; Sharma P; Allison JP; Feldman RM
    Cancer Res; 2016 Jul; 76(13):3684-9. PubMed ID: 27197182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo antitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro.
    Pham Minh N; Murata S; Kitamura N; Ueki T; Kojima M; Miyake T; Takebayashi K; Kodama H; Mekata E; Tani M
    Int J Cancer; 2018 Jun; 142(11):2335-2343. PubMed ID: 29313971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
    Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
    J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
    Ruby CE; Redmond WL; Haley D; Weinberg AD
    Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.